San Francisco, CA-based Allogene licensed Ablexis' antibodies and was granted the rights to research, develop, and commercialize certain AlivaMab antibodies against several targets.
The technology, according to Ablexis, and has been validated for antibody drug discovery by Ablexis and partners in various formats including regular antibodies, bispecifics, and CAR T cells.
Larry Green, CEO of Ablexis, said in a statement that this agreement can highlight the potential applications of AlivaMab antibodies in drug modalities such as CAR-T. Allogene is working towards the development of allogenic CAR-T therapies.
Green told us, “If using a transgenic mouse, then fully human, highly-potent, therapeutic-quality antibodies can be readily produced, which speeds the discovery phase and reduces risks in both pre-clinical and clinical development.”
Financial terms of the agreement were not disclosed.